Connective Portfolio Management LLC Has $449,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Connective Portfolio Management LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 97.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 630 shares of the biopharmaceutical company's stock after selling 25,000 shares during the period. Connective Portfolio Management LLC's holdings in Regeneron Pharmaceuticals were worth $449,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in REGN. Envestnet Asset Management Inc. raised its position in shares of Regeneron Pharmaceuticals by 12.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 75,452 shares of the biopharmaceutical company's stock valued at $79,303,000 after acquiring an additional 8,209 shares during the period. E Fund Management Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 38.2% in the second quarter. E Fund Management Co. Ltd. now owns 2,339 shares of the biopharmaceutical company's stock valued at $2,458,000 after purchasing an additional 646 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Regeneron Pharmaceuticals by 4.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 24,319 shares of the biopharmaceutical company's stock worth $25,479,000 after purchasing an additional 1,122 shares during the period. Argent Trust Co boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the second quarter. Argent Trust Co now owns 2,370 shares of the biopharmaceutical company's stock worth $2,491,000 after purchasing an additional 31 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 5.4% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,314 shares of the biopharmaceutical company's stock valued at $2,432,000 after buying an additional 119 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $10.68 during trading on Thursday, reaching $692.75. 565,381 shares of the company's stock were exchanged, compared to its average volume of 816,541. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The firm's fifty day moving average price is $746.43 and its 200-day moving average price is $956.18. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $76.13 billion, a PE ratio of 17.15, a PEG ratio of 1.60 and a beta of 0.10.

Wall Street Analyst Weigh In

Several research analysts have weighed in on REGN shares. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 target price on the stock. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Bank of America restated an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Evercore ISI lowered their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.